Nonneutralizing antibodies induced by the HIV-1 gp41 NHR domain gain neutralizing activity in the presence of the HIV fusion inhibitor enfuvirtide: A potential therapeutic vaccine strategy

Journal of Virology

Volumn 89, Issue 13, 2015, Pages 6960-6964

  Wang, Qian ^a   Bi, Wenwen ^a   Zhu, Xiaojie ^a   Li, Haoyang ^a   Qi, Qianqian ^a,b   Yu, Fei ^a   Lu, Lu ^a   Jianga, Shibo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG EFFICACY; DRUG OVERDOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; MOUSE; RABBIT; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MICE; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RABBITS;

EID: 84930916130     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00791-15     Document Type: Article

References (20)

1. Koff WC. 2012. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 30:4310-4315. http://dx.doi.org/10.1016/j.vaccine.2011.11.014.
2. Jiang S, Lin K, Strick N, Neurath AR. 1993. HIV-1 inhibition by a peptide. Nature 365:113.
3. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91:9770-9774. http://dx.doi.org/10.1073/pnas.91.21.9770.
4. Chan DC, Fass D, Berger JM, Kim PS. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273. http://dx.doi.org/10.1016/S0092-8674(00)80205-6.
5. Lu M, Blacklow SC, Kim PS. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2:1075-1082. http://dx.doi.org/10.1038/nsb1295-1075.
6. Bagai S, Lamb RA. 1997. A glycine to alanine substitution in the paramyxovirus SV5 fusion peptide increases the initial rate of fusion. Virology 238:283-290. http://dx.doi.org/10.1006/viro.1997.8858.
7. Chan DC, Kim PS. 1998. HIV entry and its inhibition. Cell 93:681-684. http://dx.doi.org/10.1016/S0092-8674(00)81430-0.
8. Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, Ingallinella P, McKenna P, Citron M, Ottinger E, Hepler RW, Hrin R, Nahas D, Wu C, Montefiori D, Shiver JW, Pessi A, Kim PS. 2010. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 107:10655-10660. http://dx.doi.org/10.1073/pnas.1004261107.
9. Qi Z, Pan C, Lu H, Shui Y, Li L, Li X, Xu X, Liu S, Jiang S. 2010. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Biochem Biophys Res Commun 398:506-512. http://dx.doi.org/10.1016/j.bbrc.2010.06.109.
10. de Rosny E, Vassell R, Wingfield PT, Wild CT, Weiss CD. 2001. Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptoractivated conformations of the envelope glycoprotein. J Virol 75:8859-8863. http://dx.doi.org/10.1128/JVI.75.18.8859-8863.2001.
11. Moore JP, Parren PWHI, Burton DR. 2001. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 75:5721-5729. http://dx.doi.org/10.1128/JVI.75.13.5721-5729.2001.
12. Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, Gorny MK, Zolla-Pazner S, Dimitrov DS, Weiss CD. 2002. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 76:6780-6790. http://dx.doi.org/10.1128/JVI.76.13.6780-6790.2002.
13. Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. 2004. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus:implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363:938-947. http://dx.doi.org/10.1016/S0140-6736(04)15788-7.
14. Pan C, Cai L, Lu H, Qi Z, Jiang S. 2009. Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains. J Virol 83:7862-7872. http://dx.doi.org/10.1128/JVI.00168-09.
15. Xu W, Wang Q, Yu F, Lu L, Jiang S. 2014. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. J Acquir Immune Defic Syndr 67:1-6. http://dx.doi.org/10.1097/QAI.0000000000000265.
16. Tong P, Lu Z, Chen X, Wang Q, Yu F, Zou P, Yu X, Li Y, Lu L, Chen YH, Jiang S. 2013. An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. J Antimicrob Chemother 68:2533-2544. http://dx .doi.org/10.1093/jac/dkt230.
17. Larder BA, Kellam P, Kemp SD. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365:451-453. http://dx.doi.org/10.1038/365451a0.
18. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681. http://dx.doi.org/10.1124/pr.58.3.10.
19. Lu L, Pan C, Li Y, Lu H, He W, Jiang S. 2012. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology 9:104. http://dx .doi.org/10.1186/1742-4690-9-104.
20. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y. 2007. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25:2832-2838. http://dx.doi.org/10.1016/j.vaccine.2006.10.031.